EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications
The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The
| Condition(s) | Opiod Use Disorder |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG |
| Who can participate | Inclusion Criteria: * For OUD Subjects: 1. Providing informed consent to participate in the study. 2. 22 to 85 years old. Having a diagnosis of OUD • OUD of more than 6 months duration as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) \[71\] with a positive urine toxicology screen who still feel craving. 4\. Lives in immediate area with no plans to relocate. For age-matched controls: 1. Providing informed consent to participate in the study. 2. 22 to 85 years old. 3. Lives in immediate area with no plans to relocate Exclusion Criteria: * For OUD Subjects: 1. Recently started on antiepileptic drug therapy. 2. Ingestion of poppy seeds or herbal teas containing Papaveris fructus (may cause a positive opiate test for morphine, codeine \[72,73\]). 3. History of neurolo |
| Ages | 22 Years to 85 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Illinois at Chicago |
| Locations | Chicago, Illinois, United States |
| Start date | 2025-02-04 |
| NCT ID | NCT07085351 |
| Official listing | https://clinicaltrials.gov/study/NCT07085351 |